BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37620532)

  • 21. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Jedrzejko N; Wong A; MacNeill AJ; Hamilton TD
    J Gastrointest Surg; 2022 Oct; 26(10):2176-2183. PubMed ID: 35852704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
    Ljunggren M; Nordenvall C; Palmer G
    Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Mercier F; Passot G; Bonnot PE; Cashin P; Ceelen W; Decullier E; Villeneuve L; Walter T; Levine EA; Glehen O; ;
    World J Surg; 2022 Jun; 46(6):1336-1343. PubMed ID: 35286418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis.
    Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
    Ann Surg Oncol; 2024 Jan; 31(1):594-604. PubMed ID: 37831280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of myometrium invasion on survival outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
    Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2023 Mar; 127(3):450-456. PubMed ID: 36285743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience.
    Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S
    Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
    Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
    Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
    Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
    Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
    Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
    World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
    Beal EW; Srinivas S; Shen C; Kim A; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Grotz TE; Leiting JL; Fournier K; Dineen S; Powers B; Veerapong J; Kothari A; Maduekew U; Maithel S; Wilson GC; Patel SH; Lambert L; Abdel-Misih S; Cloyd JM
    Ann Surg Oncol; 2023 Mar; 30(3):1840-1849. PubMed ID: 36310315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.